Reference entry

AOD-9604 (hGH Fragment 176-191)

Modified hGH Fragment · Fat Loss Peptide

Overview

AOD-9604 is a modified fragment of human growth hormone (amino acids 176-191) that stimulates lipolysis and inhibits lipogenesis without the side effects of full growth hormone. Unlike full GH, it does not increase IGF-1, affect glucose metabolism, or cause insulin resistance.

Stimulates lipolysis and inhibits lipogenesis through beta-3 adrenergic receptor upregulation, without binding to the GH receptor. Does not affect glucose metabolism or increase IGF-1 levels.

Increases fat oxidation, plasma glycerol levels, and reduces body weight in obese models without affecting glucose metabolism.

Reduces fat synthesis and storage in adipose tissue.

Does not cause hyperglycemia, reduce insulin secretion, or increase insulin resistance.

Enhanced cartilage regeneration when combined with hyaluronic acid in osteoarthritis models.

Mechanism

Stimulates lipolysis and inhibits lipogenesis through beta-3 adrenergic receptor upregulation, without binding to the GH receptor. Does not affect glucose metabolism or increase IGF-1 levels.

Increases fat oxidation, plasma glycerol levels, and reduces body weight in obese models without affecting glucose metabolism.

Research areas

AOD-9604 is a modified fragment of human growth hormone (amino acids 176-191) that stimulates lipolysis and inhibits lipogenesis without the side effects of full growth hormone. Unlike full GH, it does not increase IGF-1, affect glucose metabolism, or cause insulin resistance.
Stimulates lipolysis and inhibits lipogenesis through beta-3 adrenergic receptor upregulation, without binding to the GH receptor. Does not affect glucose metabolism or increase IGF-1 levels.
Increases fat oxidation, plasma glycerol levels, and reduces body weight in obese models without affecting glucose metabolism.
Reduces fat synthesis and storage in adipose tissue.
Does not cause hyperglycemia, reduce insulin secretion, or increase insulin resistance.
Enhanced cartilage regeneration when combined with hyaluronic acid in osteoarthritis models.
Synergistic effects with hyaluronic acid for joint health.

Research notes

Generally well-tolerated in clinical trials
Mild injection site reactions possible
No reported effects on blood glucose or insulin
Severe injection site reactions or infection signs
Unusual swelling or persistent redness
Allergic reactions (rare)
Any concerning or unexpected symptoms
Pregnancy or breastfeeding
WADA prohibited - athletes subject to testing must avoid

References

FAQs

Does AOD-9604 cause blood sugar problems like full human growth hormone?

No. AOD-9604 is a modified hGH fragment that stimulates lipolysis without binding to the GH receptor or affecting glucose metabolism. Unlike full GH which causes hyperglycemia and insulin resistance, AOD-9604 does not increase IGF-1 levels or disrupt glucose homeostasis, making it metabolically safer.

How quickly will I see fat loss with AOD-9604?

Week 1-2 shows minimal noticeable effects as compound accumulates. Week 3-4 brings subtle body composition changes. Week 5-8 produces more noticeable fat loss especially with diet and exercise. Week 8-12 shows continued fat reduction and improved body composition. Total timeline is slower than GLP-1 agonists.

Can AOD-9604 be stacked with semaglutide or other weight loss peptides?

Yes. AOD-9604's lipolytic mechanism complements semaglutide's appetite suppression through completely different pathways. However, combination data is limited. Both are safe separately; combining requires monitoring for additive dehydration/GI effects common with semaglutide.

Is there any cartilage repair evidence for AOD-9604 in humans?

Animal studies show AOD-9604 combined with hyaluronic acid enhanced cartilage regeneration in osteoarthritis models. However, this is preclinical; human cartilage repair data doesn't exist. Joint health claims should be considered theoretical unless based on clinical trial data.